soul trial oral semaglutide Presented at #ACC25: Among participants with type 2 diabetes and cardiovascular disease, chronic kidney disease, or both, (14 mg) was associated with a lower risk of cardiovascular events than placebo Oral semaglutide found to lower
Description
How should employers and other health plan sponsors think about covering or reducing the cost of covering expensive GLP-1s
These modifications extend plasma half-life and enable once-weekly
The Unmet Challenge of Medication Nonadherence
New analyses involving more than 100,000 patients suggest that users of popular diabetes and weight-loss medications face a lower risk of developing certain cancers and a reduced risk of metastasis.
